$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

$lgnd Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000088616318000063 Filed on May 09, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$56.16M	$29.27M
YoY Change	91.88%	-1.29%
Cost Of Revenue	$788.0K	$341.0K
YoY Change	131.09%	-64.29%
Gross Profit	$55.37M	$28.93M
YoY Change	91.42%	0.81%
Gross Profit Margin	98.6%	98.83%
Selling, General & Admin	$7.640M	$7.320M
YoY Change	4.37%	7.17%
% of Gross Profit	13.8%	25.31%
Research & Development	$7.407M	$8.673M
YoY Change	-14.6%	116.61%
% of Gross Profit	13.38%	29.98%
Depreciation & Amortization	$3.002M	$2.979M
YoY Change	0.77%	15.69%
% of Gross Profit	5.42%	10.3%
Operating Expenses	$7.407M	$8.673M
YoY Change	-14.6%	116.61%
Operating Profit	$37.04M	$10.22M
YoY Change	262.58%	-32.33%
Interest Expense	$3.480M	$2.941M
YoY Change	18.33%	-2.13%
% of Operating Profit	9.39%	28.79%
Other Income/Expense, Net	$18.27M	-$4.023M
YoY Change	-554.16%	-27.19%
Pretax Income	$55.31M	$6.193M
YoY Change	793.14%	-35.29%
Income Tax	$10.03M	$10.03M
% Of Pretax Income	18.14%	162.01%
Net Earnings	$45.28M	$45.28M
YoY Change	0.0%	585.21%
Net Earnings / Revenue	80.63%	154.71%
Basic Earnings Per Share	$2.13	$2.13
Diluted Earnings Per Share	$1.83	$1.83
COMMON SHARES
Basic Shares Outstanding	21.21M shares	21.21M shares
Diluted Shares Outstanding	24.80M shares	24.80M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$291.9M	$159.4M
YoY Change	83.12%	40.81%
Cash & Equivalents	$51.02M	$10.64M
Short-Term Investments	$240.9M	$148.7M
Other Short-Term Assets	$5.647M	$641.0K
YoY Change	780.97%	-58.96%
Inventory	$10.53M	$7.629M
Prepaid Expenses
Receivables	$37.10M	$7.100M
Other Receivables	$3.900M	$0.00
Total Short-Term Assets	$349.1M	$174.7M
YoY Change	99.8%	31.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.119M	$1.898M
YoY Change	117.02%	234.74%
Goodwill	$85.96M	$72.21M
YoY Change	19.05%	-1.08%
Intangibles	$225.3M	$202.0M
YoY Change	11.54%	-5.09%
Long-Term Investments	$0.00	$7.262M
YoY Change	-100.0%	-74.17%
Other Assets	$894.0K	$1.821M
YoY Change	-50.91%	2501.43%
Total Long-Term Assets	$405.6M	$455.0M
YoY Change	-10.86%	-5.28%
TOTAL ASSETS
Total Short-Term Assets	$349.1M	$174.7M
Total Long-Term Assets	$405.6M	$455.0M
Total Assets	$754.7M	$629.7M
YoY Change	19.84%	2.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.407M	$6.456M
YoY Change	-47.23%	140.18%
Accrued Expenses	$8.480M	$4.680M
YoY Change	81.2%	27.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$227.5M	$215.7M
YoY Change	5.47%	35850.0%
Total Short-Term Liabilities	$247.0M	$227.0M
YoY Change	8.8%	1754.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$26.90M
YoY Change	-100.0%	-86.86%
Other Long-Term Liabilities	$1.135M	$915.0K
YoY Change	24.04%	105.16%
Total Long-Term Liabilities	$1.135M	$915.0K
YoY Change	24.04%	105.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$247.0M	$227.0M
Total Long-Term Liabilities	$1.135M	$915.0K
Total Liabilities	$257.5M	$230.9M
YoY Change	11.49%	4.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$327.4M	-$408.4M
YoY Change	-19.83%	3.29%
Common Stock	$21.00K	$21.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$481.1M	$371.8M
YoY Change
Total Liabilities & Shareholders Equity	$754.7M	$629.7M
YoY Change	19.84%	2.65%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$45.28M	$45.28M
YoY Change	0.0%	585.21%
Depreciation, Depletion And Amortization	$3.002M	$2.979M
YoY Change	0.77%	15.69%
Cash From Operating Activities	$60.76M	$19.22M
YoY Change	216.07%	46.59%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	$87.00K
YoY Change	-329.89%	-63.45%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$1.240M	$87.00K
YoY Change	1325.29%	-100.11%
Cash From Investing Activities	-$33.58M	-$25.67M
YoY Change	30.83%	-67.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.895M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.224M	-$1.667M
YoY Change	-293.4%	-426.22%
NET CHANGE
Cash From Operating Activities	$60.76M	$19.22M
Cash From Investing Activities	-$33.58M	-$25.67M
Cash From Financing Activities	$3.224M	-$1.667M
Net Change In Cash	$30.40M	-$8.111M
YoY Change	-474.85%	-87.74%
FREE CASH FLOW
Cash From Operating Activities	$60.76M	$19.22M
Capital Expenditures	-$200.0K	$87.00K
Free Cash Flow	$60.96M	$19.14M
YoY Change	218.55%	48.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000886163
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21301400	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	LIGAND PHARMACEUTICALS INC
CY2017Q1	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	3909000	USD
CY2018Q1	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	1180000	USD
CY2017Q1	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	3916000	USD
CY2018Q1	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	30946000	USD
CY2017Q4	lgnd	Commercial License Rights CommercialLicenseRights	19526000	USD
CY2018Q1	lgnd	Commercial License Rights CommercialLicenseRights	19969000	USD
CY2017Q4	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	4703000	USD
CY2017Q1	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	0	USD
CY2018Q1	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	1000000	USD
CY2018Q1	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	1000000	USD
CY2014Q3	lgnd	Paymentsfor Convertible Bond Hedges PaymentsforConvertibleBondHedges	48100000	USD
CY2018Q1	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	7545000	USD
CY2017Q4	lgnd	Equity Securities Fvni EquitySecuritiesFVNI	0	USD
CY2018Q1	lgnd	Equity Securities Fvni EquitySecuritiesFVNI	27535000	USD
CY2014Q3	lgnd	Exercise Priceof Convertible Bond Hedge ExercisePriceofConvertibleBondHedge	75.05
CY2017Q1	lgnd	Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant	76000	USD
CY2018Q1	lgnd	Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant	748000	USD
CY2017Q4	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	9258000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7377000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8480000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	430000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	497000	USD
CY2018Q1	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	6376000	USD
CY2017Q1	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-140000	USD
CY2018Q1	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-960000	USD
CY2017Q1	lgnd	Paymentsto Cvr Holdersand Other Contingency Payments PaymentstoCVRHoldersandOtherContingencyPayments	4998000	USD
CY2018Q1	lgnd	Paymentsto Cvr Holdersand Other Contingency Payments PaymentstoCVRHoldersandOtherContingencyPayments	0	USD
CY2018Q1	lgnd	Revenue Recognition Milestone Method Milestone Payment Received RevenueRecognitionMilestoneMethodMilestonePaymentReceived	4600000	USD
CY2018Q1	lgnd	Revenue Recognition Milestone Method Third Party Portionof Milestone Payment Received RevenueRecognitionMilestoneMethodThirdPartyPortionofMilestonePaymentReceived	3000000	USD
CY2017Q3	lgnd	Working Capital Deficit WorkingCapitalDeficit	102100000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2259000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3407000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	954000	USD
CY2018Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1043000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2486000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-286000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	798205000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	808765000	USD
CY2014Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11600000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	6045000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	4555000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2838000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3018000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3711067	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	148404	shares
CY2017Q4	us-gaap	Assets Assets	671021000	USD
CY2018Q1	us-gaap	Assets Assets	754668000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	237021000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	349051000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	181041000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	213329000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1695000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1582000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	182000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	373000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	179528000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	212120000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-140000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-960000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18752000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10641000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20620000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51024000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8111000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30404000	USD
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	125.08
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3264643	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21148665	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21301980	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21148665	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21301980	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5441000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	45130000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	224529000	USD
CY2018Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	227547000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	341000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	788000	USD
CY2017Q1	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	2715000	USD
CY2018Q1	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	3278000	USD
CY2017Q4	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	18859000	USD
CY2018Q1	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	16078000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	84422000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	69368000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	173000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	75000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3525000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3000000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2979000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3002000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.22
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.83
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.18
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.18
CY2017Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4085000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1455000	USD
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	6438000	USD
CY2018Q1	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2017Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1083000	USD
CY2018Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	21097000	USD
CY2018Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	21100000	USD
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1719099	shares
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	55312000	USD
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1083000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7322000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7643000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	85959000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	85961000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6193000	USD
CY2018Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	21183000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1114000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10033000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	96000	USD
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	171000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1963000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	321000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7643000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11512000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1018000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-9862000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1197000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4978000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-633000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	522000	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	688852	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	941308	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	954509	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1119611	shares
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	228584000	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	225306000	USD
CY2017Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	314543000	USD
CY2018Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	311267000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	2941000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	2605000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	919000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	919000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	396000	USD
CY2018Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3417000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	4373000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	10531000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	252374000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	257490000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	671021000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	754668000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	238868000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	246979000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1667000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3224000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25668000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33581000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19224000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	60761000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	5079000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	45279000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4023000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18271000	USD
CY2017Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	3877000	USD
CY2018Q1	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	3877000	USD
CY2017Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	19051000	USD
CY2018Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	19116000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	10216000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	37041000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1339000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1993000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1514000	USD
CY2018Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5647000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4859000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	894000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-66000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-149000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-428000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	723000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1135000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	141000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	739000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	87000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	240000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1895000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2022000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3797000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	73352000	USD
CY2018Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	98957000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	30052000	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	54325000	USD
CY2017Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	0	USD
CY2018Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	32707000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	17719000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	12291000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	355000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8916000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	5079000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	45279000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4212000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4119000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	25596000	USD
CY2018Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	37108000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8673000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7407000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400924000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-327400000	USD
CY2018Q1	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	1600000	USD
CY2017Q1	us-gaap	Revenues Revenues	29267000	USD
CY2018Q1	us-gaap	Revenues Revenues	56157000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	24230000	USD
CY2018Q1	us-gaap	Royalty Revenue RoyaltyRevenue	20820000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1121000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4391000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6045000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4555000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.47
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.33
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	63.43
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	64.73
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	159.02
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y11M
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1945526	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	53.17
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.027
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1300000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	39.09
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	202994	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1876332	shares
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	181041000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	213329000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	133800	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	399788000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	481100000	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-66000	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23019000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23019189	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24800000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24800314	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20937627	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21208793	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20938000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21209000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	185745	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	63959	shares
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000886163-18-000063-index-headers.html	Edgar Link	pending
0000886163-18-000063-index.html	Edgar Link	pending
0000886163-18-000063.txt	Edgar Link	pending
0000886163-18-000063-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
finalligand-roivantgralice.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lgnd-20180331.xml	Edgar Link	completed
lgnd-20180331.xsd	Edgar Link	pending
lgnd-20180331_cal.xml	Edgar Link	unprocessable
lgnd-20180331_def.xml	Edgar Link	unprocessable
lgnd-20180331_lab.xml	Edgar Link	unprocessable
lgnd-20180331_pre.xml	Edgar Link	unprocessable
lgnd-3311810q.htm	Edgar Link	pending
lgnd-ctrxretrophinredacted.htm	Edgar Link	pending
lgnd_33118exhibit311.htm	Edgar Link	pending
lgnd_33118exhibit312.htm	Edgar Link	pending
lgnd_33118exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

2018 Q1 Form 10-Q Financial Statement

#000088616318000063 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND LIGAND PHARMACEUTICALS INC Stock $lgnd

2018 Q1 Form 10-Q Financial Statement

#000088616318000063 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd